Cardio Diagnostics Holdings, Inc.
Business
Cardio Diagnostics Holdings develops and commercializes AI-driven epigenetics-based clinical blood tests for cardiovascular disease risk assessment and detection. The company's primary products are Epi+Gen CHD™ for three-year coronary heart disease event risk assessment and PrecisionCHD™ for early detection of coronary heart disease, both laboratory-developed tests offered through its CLIA-certified laboratory. Cardio also offers Actionable Clinical Intelligence™ (a provider-facing platform), CardioInnovate360™ (a research-use-only solution), and HeartRisk™ (a cardiovascular disease risk intelligence platform). The company pursues multiple revenue channels including health systems, employers, concierge practices, and telemedicine platforms, with expansion into international markets including India.
Summary from 10-K filed 2026-03-13
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 14,825 | 34,890 | 17,065 | 950 | 901 | |
| Sales and marketing | 766,888 | 1 | 158,514 | 92,700 | 103,318 | |
| Research and development | 641,212 | 227,966 | 145,182 | 40,448 | 31,468 | |
| General and administrative | 5 | 7 | 7 | 4 | 470,563 | |
| Amortization | 65,233 | 19,738 | 19,182 | 16,000 | 16,000 | |
| Total operating expenses | 6 | 8 | 7 | 5 | 621,349 | |
| Loss from operations | −6 | −8 | −7 | −5 | −620,448 | |
| Interest income | 712 | 1,064 | 1,068 | — | — | |
| Interest expense | −14,801 | −18,640 | −7 | — | — | |
| Total other income (expenses) | −14,089 | −17,576 | −1 | −112,534 | — | |
| Loss before provision for income taxes | −6 | −8 | −8 | −5 | −620,448 | |
| Provision for income taxes | — | — | — | — | 0 | |
| Net loss | −6 | −8 | −8 | −5 | −620,448 | |
| Net loss per common share, basic | −3.71 | −9.35 | −0.66 | −1.51 | −0.53 | |
| Net loss per common share, diluted | −3.71 | −9.35 | −0.66 | −1.51 | −0.53 | |
| Weighted average common shares outstanding, basic | 2 | 896,424 | 13 | 3 | 1 | |
| Weighted average common shares outstanding, fully diluted | 2 | 896,424 | 13 | 3 | 1 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2023 2023-07-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash | 5 | 8 | 1 | — | 4 | |
| Accounts receivable | 8,126 | 18,612 | 4,960 | — | — | |
| Prepaid expenses and other current assets | 801,947 | 944,683 | 1 | — | 2 | |
| Total current assets | 6 | 9 | 3 | — | 6 | |
| Property and equipment, net | 700,115 | 672,861 | 571,873 | — | — | |
| Right of use assets, net | 259,565 | 432,397 | 575,227 | 663,875 | — | |
| Intangible assets, net | — | 5,333 | 21,333 | — | 37,333 | |
| Deposits | 12,850 | 12,850 | 12,850 | — | 4,950 | |
| Patent costs, net | 873,182 | 701,089 | 515,402 | — | 321,308 | |
| Total assets | 8 | 11 | 4 | — | 6 | |
| Accounts payable and accrued expenses | 97,442 | 87,661 | 243,213 | — | 1 | |
| Lease liability - current | 237,607 | 237,270 | 223,929 | — | — | |
| Finance agreement payable | 269,790 | 306,764 | 374,000 | — | 849,032 | |
| Total current liabilities | 604,839 | 631,695 | 841,142 | — | 2 | |
| Lease liability - long term | 188,222 | 425,829 | 663,099 | — | — | |
| Total liabilities | 793,061 | 1 | 2 | — | 2 | |
| Preferred stock, $.00001 par value; authorized - 100,000,000 shares; 0 shares issued and outstanding as of December 31, 2025 and 2024, respectively | — | — | — | — | — | |
| Common stock, $.00001 par value; authorized - 300,000,000 shares; 1,826,051 and 1,531,468 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 18 | 15 | 205 | — | 95 | |
| Additional paid-in capital | 36 | 32 | 17 | — | 10 | |
| Accumulated deficit | −29 | −23 | −14 | — | −6 | |
| Total stockholders' equity | 7 | 10 | 3 | — | 4 | |
| Total liabilities and stockholders' equity | 8 | 11 | 4 | — | 6 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 160,063 | 113,777 | 3,790 | 0 | — | |
| Amortization | 238,065 | 162,568 | 107,830 | 16,000 | 16,000 | |
| Stock-based compensation expense | 110,235 | 3 | 1 | — | 60,000 | |
| Accounts receivable | 10,486 | −13,652 | −4,960 | 901 | −901 | |
| Prepaid expenses and other current assets | 479,974 | 915,969 | 758,669 | −690,821 | — | |
| Accounts payable and accrued expenses | 9,781 | −155,552 | −781,500 | 136,353 | −5,654 | |
| Lease liability | −237,270 | −223,929 | 244,505 | — | — | |
| NET CASH USED IN OPERATING ACTIVITIES | −6 | −5 | −6 | −5 | −585,291 | |
| Purchases of property and equipment | −187,317 | −214,765 | −575,663 | — | — | |
| Patent costs incurred | −231,993 | −189,425 | −197,276 | −76,154 | −114,029 | |
| NET CASH USED IN INVESTING ACTIVITIES | −419,310 | −404,190 | −794,291 | −368,001 | −364,029 | |
| Proceeds from sale of common stock and warrants, net of issuance costs | 4 | 12 | — | 12 | 105,000 | |
| Payments of finance agreement | −374,212 | −450,691 | −942,532 | −188,674 | — | |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 3 | 12 | 4 | 9 | 1 | |
| NET (DECREASE) INCREASE IN CASH | −3 | 7 | −3 | 4 | 275,680 | |
| Interest | 14,801 | 18,640 | 30,491 | 5,829 | 0 | |
| Income taxes | — | — | — | — | — | |
| Financing agreement entered into for prepaid insurance | 337,238 | 383,455 | 467,500 | 1 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Cardio Diagnostics Holdings, Inc.'s CIK number?
Cardio Diagnostics Holdings, Inc.'s SEC CIK number is 0001870144 (1870144). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Cardio Diagnostics Holdings, Inc.'s SEC filings?
All of Cardio Diagnostics Holdings, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.